F. Gasparini

45.7k total citations · 1 hit paper
123 papers, 7.8k citations indexed

About

F. Gasparini is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Cognitive Neuroscience. According to data from OpenAlex, F. Gasparini has authored 123 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Cellular and Molecular Neuroscience, 53 papers in Molecular Biology and 20 papers in Cognitive Neuroscience. Recurrent topics in F. Gasparini's work include Neuroscience and Neuropharmacology Research (73 papers), Receptor Mechanisms and Signaling (23 papers) and Genetics and Neurodevelopmental Disorders (15 papers). F. Gasparini is often cited by papers focused on Neuroscience and Neuropharmacology Research (73 papers), Receptor Mechanisms and Signaling (23 papers) and Genetics and Neurodevelopmental Disorders (15 papers). F. Gasparini collaborates with scholars based in Switzerland, Italy and United States. F. Gasparini's co-authors include Will Spooren, Rainer Kühn, Baltazar Gomez‐Mancilla, Peter J. Flor, Athina Markou, Ivo Vranesic, Ralf Kühn, Thérèse Di Paolo, Natacha Stoehr and Paul J. Kenny and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Neuroscience and NeuroImage.

In The Last Decade

F. Gasparini

120 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist

1999 628 citations F. Gasparini, Kurt Lingenhöhl et al. Neuropharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Gasparini Switzerland	50	5.7k	4.1k	1.5k	858	824	123	7.8k
Qiang Zhou China	27	4.9k 0.9×	3.1k 0.8×	1.6k 1.1×	735 0.9×	666 0.8×	69	7.0k
Robert T. Fremeau United States	37	5.7k 1.0×	4.8k 1.2×	1.3k 0.9×	343 0.4×	974 1.2×	61	9.0k
David J. A. Wyllie United Kingdom	46	4.5k 0.8×	4.3k 1.0×	1.3k 0.9×	623 0.7×	672 0.8×	100	6.9k
Colleen M. Niswender United States	47	6.3k 1.1×	6.6k 1.6×	902 0.6×	468 0.5×	420 0.5×	249	9.2k
Hari Manev United States	45	3.0k 0.5×	3.0k 0.7×	797 0.5×	396 0.5×	1.1k 1.3×	183	7.3k
Kasper B. Hansen United States	35	5.1k 0.9×	4.2k 1.0×	730 0.5×	456 0.5×	518 0.6×	86	6.9k
Steven Mennerick United States	54	6.1k 1.1×	4.5k 1.1×	1.7k 1.1×	369 0.4×	2.0k 2.4×	187	10.3k
Claudio Rivera Finland	40	6.2k 1.1×	4.3k 1.1×	1.6k 1.1×	537 0.6×	716 0.9×	85	8.6k
James H. Meador‐Woodruff United States	61	6.3k 1.1×	5.2k 1.3×	1.9k 1.3×	978 1.1×	973 1.2×	204	10.9k
Christophe Mulle France	53	6.5k 1.1×	5.4k 1.3×	2.2k 1.5×	391 0.5×	839 1.0×	124	9.4k

Countries citing papers authored by F. Gasparini

Since Specialization

Citations

This map shows the geographic impact of F. Gasparini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Gasparini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Gasparini more than expected).

Fields of papers citing papers by F. Gasparini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Gasparini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Gasparini. The network helps show where F. Gasparini may publish in the future.

Co-authorship network of co-authors of F. Gasparini

This figure shows the co-authorship network connecting the top 25 collaborators of F. Gasparini. A scholar is included among the top collaborators of F. Gasparini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Gasparini. F. Gasparini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Neri, Marilisa, Mario Bernhard, Irena Brzak, et al.. (2022). Sustained Trem2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer’s disease. Cell Reports. 39(9). 110883–110883. 33 indexed citations

Berry‐Kravis, Elizabeth, Lothar Lindemann, Aia Elise Jønch, et al.. (2017). Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nature Reviews Drug Discovery. 17(4). 280–299. 233 indexed citations

Lakkaraju, Asvin KK, Amulya Nidhi Shrivastava, Silvia Sorce, et al.. (2017). Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity. PLoS Pathogens. 13(11). e1006733–e1006733. 38 indexed citations

DeLorenzo, Christine, Jean‐Dominique Gallezot, Jie Yang, et al.. (2016). In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [¹¹C]ABP688 and [¹⁸F]FPEB. Journal of Cerebral Blood Flow & Metabolism. 37(8). 2716–2727. 41 indexed citations

Hagerman, Randi J., Vincent Desportes, F. Gasparini, Sébastien Jacquemont, & Baltazar Gomez‐Mancilla. (2014). Translating Molecular Advances in Fragile X Syndrome Into Therapy. The Journal of Clinical Psychiatry. 75(4). e294–e307. 40 indexed citations

Rascol, Olivier, Susan H. Fox, F. Gasparini, et al.. (2014). Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. Parkinsonism & Related Disorders. 20(9). 947–956. 88 indexed citations

Jacquemont, Sébastien, Elizabeth Berry‐Kravis, Randi J. Hagerman, et al.. (2013). The challenges of clinical trials in fragile X syndrome. Psychopharmacology. 231(6). 1237–1250. 91 indexed citations

Morin, Nicolas, Marc Morissette, Laurent Grégoire, et al.. (2013). Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in l-DOPA-treated parkinsonian monkeys. Neuropharmacology. 73. 216–231. 50 indexed citations

Gantois, Ilse, Andreea Pop, Celine de Esch, et al.. (2012). Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behavioural Brain Research. 239. 72–79. 78 indexed citations

10.

Tabolacci, Elisabetta, Filomena Pirozzi, Baltazar Gomez‐Mancilla, F. Gasparini, & Giovanni Neri. (2012). The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro. BMC Medical Genetics. 13(1). 13–13. 14 indexed citations

11.

Inta, Dragoš, Dragana Filipović, Juan M. Lima‐Ojeda, et al.. (2012). The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: Significance for the use as anxiolytic/antidepressant drug. Neuropharmacology. 62(5-6). 2034–2039. 27 indexed citations

12.

Levenga, Josien, Shigemi Hayashi, Femke M.S. de Vrij, et al.. (2011). AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiology of Disease. 42(3). 311–317. 101 indexed citations

13.

Ouattara, Bazoumana, Daniël Hoyer, Laurent Grégoire, et al.. (2010). Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience. 167(4). 1160–1167. 41 indexed citations

14.

Jolivet, Renaud, et al.. (2009). BLOCKADE OF THE METABOTROPIC GLUTAMATE RECEPTOR MGLUR5 DOES NOT AFFECT NEUROVASCULAR COUPLING IN ADULT SPRAGUE-DAWLEY RATS. UCL Discovery (University College London). 1 indexed citations

15.

Benettoni, M., F. Gasparini, F. Gonella, et al.. (2007). CMS DT Chambers: Optimized Measurement of Cosmic Rays Crossing Time in absence of Magnetic Field. CERN Bulletin. 3 indexed citations

16.

Hintermann, Samuel, Ivo Vranesic, Hans Allgeier, et al.. (2006). ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies. Bioorganic & Medicinal Chemistry. 15(2). 903–914. 55 indexed citations

17.

Kenny, Paul J., F. Gasparini, & Athina Markou. (2003). Group II Metabotropic and α-Amino-3-hydroxy-5-methyl-4-isoxazole Propionate (AMPA)/Kainate Glutamate Receptors Regulate the Deficit in Brain Reward Function Associated with Nicotine Withdrawal in Rats. Journal of Pharmacology and Experimental Therapeutics. 306(3). 1068–1076. 117 indexed citations

18.

Gasparini, F., Hendrik Andres, Peter J. Flor, et al.. (2002). [3H]-M-MPEP, a Potent, Subtype-Selective Radioligand for the Metabotropic Glutamate Receptor Subtype 5. Bioorganic & Medicinal Chemistry Letters. 12(3). 407–409. 63 indexed citations

19.

Thomas, Lisa, David E. Jane, F. Gasparini, & Martin J. Croucher. (2001). Glutamate release inhibiting properties of the novel mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP): complementary in vitro and in vivo evidence. Neuropharmacology. 41(4). 523–527. 46 indexed citations

20.

Salt, T.E., K. E. Binns, J.P. Turner, F. Gasparini, & Ralf Kühn. (1999). Antagonism of the mGlu5 agonist 2‐chloro‐5‐hydroxyphenylglycine by the novel selective mGlu5 antagonist 6‐methyl‐2‐(phenylethynyl)‐pyridine (MPEP) in the thalamus. British Journal of Pharmacology. 127(5). 1057–1059. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact